Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Eikon Therapeutics, Inc. (EIKN) had Return on Tangible Equity of -15.06% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-82.96M |
|
-- |
|
-- |
|
$87.34M |
|
$-87.34M |
|
$4.38M |
|
$-82.96M |
|
$-82.96M |
|
$-82.96M |
|
$-82.96M |
|
$-82.96M |
|
$-82.96M |
|
$-87.34M |
|
$-82.22M |
|
33.70M |
|
33.70M |
|
$-2.46 |
|
$-2.46 |
|
| Balance Sheet Financials | |
$529.50M |
|
$138.07M |
|
$321.32M |
|
$850.83M |
|
$45.06M |
|
-- |
|
$255.09M |
|
$300.15M |
|
$550.67M |
|
$550.67M |
|
$550.67M |
|
54.14M |
|
| Cash Flow Statement Financials | |
$-89.80M |
|
$-203.22M |
|
$349.31M |
|
$113.07M |
|
$169.36M |
|
$56.29M |
|
$2.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-90.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.06% |
|
|
Return on Tangible Equity |
-15.06% |
-9.75% |
|
-15.06% |
|
$10.17 |
|
$-2.67 |
|
$-2.66 |
|